BIOR - Biora Therapeutics Inc
IEX Last Trade
0.6973
0.012 1.649%
Share volume: 81,309
Last Updated: Fri 30 Aug 2024 09:59:52 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.69
0.01
1.68%
Fundamental analysis
32%
Profitability
49%
Dept financing
31%
Liquidity
12%
Performance
20%
Performance
5 Days
2.79%
1 Month
2.52%
3 Months
14.60%
6 Months
-50.92%
1 Year
-75.72%
2 Year
-1.51%
Key data
Stock price
$0.70
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.48 - $3.38
52 WEEK CHANGE
-$0.77
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Harry Stylli
Region: US
Website: https://www.progenity.com/
Employees: 157
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.progenity.com/
Employees: 157
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.
Recent news